David Mack

List of Publications by Year in descending order

42 papers	5,954 citations	172386 29 h-index	265120 42 g-index
44 all docs	44 docs citations	44 times ranked	8697 citing authors

#	Article	IF	Citations
1	Tolerability and SCFA production after resistant starch supplementation in humans: a systematic review of randomized controlled studies. American Journal of Clinical Nutrition, 2022, 115, 608-618.	2.2	14
2	Anti-Microbial Antibody Response is Associated With Future Onset of Crohnâ€™s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology, 2021, 161, 1540-1551.	0.6	35
3	Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 580-585.	0.9	8
4	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohnâ€™s disease subjects. BMC Medical Genetics, 2020, 21, 204.	2.1	11
5	Increased Intestinal Permeability Is Associated With Later Development of Crohnâ€™s Disease. Gastroenterology, 2020, 159, 2092-2100.e5.	0.6	156
6	Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohnâ€™s disease. Nature Communications, 2020, 11, 4120.	5.8	32
7	The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis. BMC Gastroenterology, 2020, 20, 372.	0.8	17
8	CpG Methylation in TGFÎ²1 and IL-6 Genes as Surrogate Biomarkers for Diagnosis of IBD in Children. Inflammatory Bowel Diseases, 2020, 26, 1572-1578.	0.9	9
9	Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2019, 25, 1796-1804.	0.9	21
10	The mucosalâ€“luminal interface: an ideal sample to study the mucosa-associated microbiota and the intestinal microbial biogeography. Pediatric Research, 2019, 85, 895-903.	1.1	32
11	Blenderized Enteral Nutrition Diet Study: Feasibility, Clinical, and Microbiome Outcomes of Providing Blenderized Feeds Through a Gastric Tube in a Medically Complex Pediatric Population. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1046-1060.	1.3	85
12	Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 829-838.	0.9	23
13	Independent of Birth Mode or Gestational Age, Very-Low-Birth-Weight Infants Fed Their Mothers' Milk Rapidly Develop Personalized Microbiotas Low in Bifidobacterium. Journal of Nutrition, 2018, 148, 326-335.	1.3	22
14	Children's perspectives on the benefits and burdens of research participation. AJOB Empirical Bioethics, 2018, 9, 19-28.	0.8	20
15	Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host and Microbe, 2018, 24, 600-610.e4.	5.1	193
16	Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. Nature Communications, 2018, 9, 2873.	5.8	209
17	Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 254-260.	0.9	81
18	Deep Metaproteomics Approach for the Study of Human Microbiomes. Analytical Chemistry, 2017, 89, 9407-9415.	3.2	83

#	Article	IF	Citations
19	Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children. JAMA Pediatrics, 2017, 171, 984.	3.3	33
20	Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 2017, 152, 206-217.e2.	0.6	120
21	Allied Health Professional Support in Pediatric Inflammatory Bowel Disease: A Survey from the Canadian Children Inflammatory Bowel Disease Networkâ€”A Joint Partnership of CIHR and the CH.I.L.D. Foundation. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-7.	0.8	10
22	Mucosa-Associated Ileal Microbiota in New-Onset Pediatric CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, 1533-1539.	0.9	43
23	Histologic analysis of eosinophils and mast cells of the gastrointestinal tract in healthy Canadian children. Human Pathology, 2016, 54, 55-63.	1.1	31
24	Value of histopathology for predicting the post-operative complications of ileo-anal anastomosis (J-pouch) procedure in children with refractory ulcerative colitis. Pathology, 2016, 48, 330-335.	0.3	4
25	To tell or not to tell: A qualitative interview study on disclosure decisions among children with inflammatory bowel disease. Social Science and Medicine, 2016, 162, 115-123.	1.8	42
26	Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping. PLoS ONE, 2015, 10, e0128074.	1.1	35
27	Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. Journal of Pediatrics, 2015, 167, 527-532.e3.	0.9	81
28	Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1748-1756.	2.4	90
29	Functional Impacts of the Intestinal Microbiome in the Pathogenesis of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 139-153.	0.9	112
30	Gut microbiota of the very-low-birth-weight infant. Pediatric Research, 2015, 77, 205-213.	1.1	85
31	Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2014, 5, e46.	1.3	71
32	Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-Î± vs an Immunomodulator in Children With Crohn's Disease. Gastroenterology, 2014, 146, 383-391.	0.6	224
33	The Treatment-Naive Microbiome in New-Onset Crohnâ€™s Disease. Cell Host and Microbe, 2014, 15, 382-392.	5.1	2,582
34	Variants in Nicotinamide Adenine Dinucleotide Phosphate Oxidase Complex Components Determine Susceptibility to Very Early Onset Inflammatory Bowel Disease. Gastroenterology, 2014, 147, 680-689.e2.	0.6	106
35	Mathematical weighting of the pediatric CrohnÊ¼s disease activity index (PCDAI) and comparison with its other short versions. Inflammatory Bowel Diseases, 2012, 18, 55-62.	0.9	203
36	Probiotics in Inflammatory Bowel Diseases and Associated Conditions. Nutrients, 2011, 3, 245-264.	1.7	62

#	Article	IF	Citations
37	Appraisal of the Pediatric Crohn's Disease Activity Index on Four Prospectively Collected Datasets: Recommended Cutoff Values and Clinimetric Properties. American Journal of Gastroenterology, 2010, 105, 2085-2092.	0.2	122
38	Long-term outcome of maintenance infliximab therapy in children with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 816-822.	0.9	165
39	Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children. Clinical Gastroenterology and Hepatology, 2008, 6, 1105-1111.	2.4	231
40	Intercenter variation in initial management of children with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2007, 13, 890-895.	0.9	67
41	Corticosteroid Therapy in the Age of Infliximab: Acute and 1-Year Outcomes in Newly Diagnosed Children With Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1124-1129.	2.4	112
42	Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience. Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 416-421.	0.9	271